Red blood cell-like particles with the ability to avoid lung and spleen accumulation for the treatment of liver fibrosis

Koichiro Hayashi, Shota Yamada, Hikaru Hayashi, Wataru Sakamoto, Toshinobu Yogo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Micro-sized drug-carrier particles accumulate mainly in the lungs and nano-sized particles tend to accumulate in the liver and spleen. Here, we show that micro-particles designed to mimic red blood cells (RBCs) can overcome these limitations. The RBC-MPs created in this study have a unique intra-particle elasticity distribution (IED), enabling them to bend around the central axis of the RBC-like dent, enabling them to pass through pores smaller than their diameter, mechanically behaving as authentic RBCs. In contrast, spherical MPs (SPH-MPs) and RBC-MPs hardened by incorporating a siloxane network (SiO2-RBC-MPs), could not. In addition to the IED, we discovered that the deformability also depends on the shape and average particle elasticity. RBC-MPs did not accumulate in the lungs and the spleen, but were targeted specifically to the liver instead. In contrast, non-RBC-MPs such as SPH-MPs and SiO2-RBC-MPs showed heavy accumulation in the lungs and/or spleen, and were dispersed non-specifically in various organs. Thus, controlling the shape and mechanical properties of RBC-MPs is important for achieving the desired biodistribution. When RBC-MPs were loaded with a (TGF)-β receptor inhibitor, RBC-MPs could treat liver fibrosis without pneumotoxicity.

Original languageEnglish
Pages (from-to)45-55
Number of pages11
JournalBiomaterials
Volume156
DOIs
Publication statusPublished - Feb 1 2018
Externally publishedYes

Fingerprint

Liver Cirrhosis
Liver
Blood
Spleen
Erythrocytes
Cells
Lung
Elasticity
Therapeutics
Siloxanes
Drug Carriers
Formability
Blood Cells
Mechanical properties

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Red blood cell-like particles with the ability to avoid lung and spleen accumulation for the treatment of liver fibrosis. / Hayashi, Koichiro; Yamada, Shota; Hayashi, Hikaru; Sakamoto, Wataru; Yogo, Toshinobu.

In: Biomaterials, Vol. 156, 01.02.2018, p. 45-55.

Research output: Contribution to journalArticle

Hayashi, Koichiro ; Yamada, Shota ; Hayashi, Hikaru ; Sakamoto, Wataru ; Yogo, Toshinobu. / Red blood cell-like particles with the ability to avoid lung and spleen accumulation for the treatment of liver fibrosis. In: Biomaterials. 2018 ; Vol. 156. pp. 45-55.
@article{55c4bc4b354643b7b943c69bd157202c,
title = "Red blood cell-like particles with the ability to avoid lung and spleen accumulation for the treatment of liver fibrosis",
abstract = "Micro-sized drug-carrier particles accumulate mainly in the lungs and nano-sized particles tend to accumulate in the liver and spleen. Here, we show that micro-particles designed to mimic red blood cells (RBCs) can overcome these limitations. The RBC-MPs created in this study have a unique intra-particle elasticity distribution (IED), enabling them to bend around the central axis of the RBC-like dent, enabling them to pass through pores smaller than their diameter, mechanically behaving as authentic RBCs. In contrast, spherical MPs (SPH-MPs) and RBC-MPs hardened by incorporating a siloxane network (SiO2-RBC-MPs), could not. In addition to the IED, we discovered that the deformability also depends on the shape and average particle elasticity. RBC-MPs did not accumulate in the lungs and the spleen, but were targeted specifically to the liver instead. In contrast, non-RBC-MPs such as SPH-MPs and SiO2-RBC-MPs showed heavy accumulation in the lungs and/or spleen, and were dispersed non-specifically in various organs. Thus, controlling the shape and mechanical properties of RBC-MPs is important for achieving the desired biodistribution. When RBC-MPs were loaded with a (TGF)-β receptor inhibitor, RBC-MPs could treat liver fibrosis without pneumotoxicity.",
author = "Koichiro Hayashi and Shota Yamada and Hikaru Hayashi and Wataru Sakamoto and Toshinobu Yogo",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2017.11.031",
language = "English",
volume = "156",
pages = "45--55",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Red blood cell-like particles with the ability to avoid lung and spleen accumulation for the treatment of liver fibrosis

AU - Hayashi, Koichiro

AU - Yamada, Shota

AU - Hayashi, Hikaru

AU - Sakamoto, Wataru

AU - Yogo, Toshinobu

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Micro-sized drug-carrier particles accumulate mainly in the lungs and nano-sized particles tend to accumulate in the liver and spleen. Here, we show that micro-particles designed to mimic red blood cells (RBCs) can overcome these limitations. The RBC-MPs created in this study have a unique intra-particle elasticity distribution (IED), enabling them to bend around the central axis of the RBC-like dent, enabling them to pass through pores smaller than their diameter, mechanically behaving as authentic RBCs. In contrast, spherical MPs (SPH-MPs) and RBC-MPs hardened by incorporating a siloxane network (SiO2-RBC-MPs), could not. In addition to the IED, we discovered that the deformability also depends on the shape and average particle elasticity. RBC-MPs did not accumulate in the lungs and the spleen, but were targeted specifically to the liver instead. In contrast, non-RBC-MPs such as SPH-MPs and SiO2-RBC-MPs showed heavy accumulation in the lungs and/or spleen, and were dispersed non-specifically in various organs. Thus, controlling the shape and mechanical properties of RBC-MPs is important for achieving the desired biodistribution. When RBC-MPs were loaded with a (TGF)-β receptor inhibitor, RBC-MPs could treat liver fibrosis without pneumotoxicity.

AB - Micro-sized drug-carrier particles accumulate mainly in the lungs and nano-sized particles tend to accumulate in the liver and spleen. Here, we show that micro-particles designed to mimic red blood cells (RBCs) can overcome these limitations. The RBC-MPs created in this study have a unique intra-particle elasticity distribution (IED), enabling them to bend around the central axis of the RBC-like dent, enabling them to pass through pores smaller than their diameter, mechanically behaving as authentic RBCs. In contrast, spherical MPs (SPH-MPs) and RBC-MPs hardened by incorporating a siloxane network (SiO2-RBC-MPs), could not. In addition to the IED, we discovered that the deformability also depends on the shape and average particle elasticity. RBC-MPs did not accumulate in the lungs and the spleen, but were targeted specifically to the liver instead. In contrast, non-RBC-MPs such as SPH-MPs and SiO2-RBC-MPs showed heavy accumulation in the lungs and/or spleen, and were dispersed non-specifically in various organs. Thus, controlling the shape and mechanical properties of RBC-MPs is important for achieving the desired biodistribution. When RBC-MPs were loaded with a (TGF)-β receptor inhibitor, RBC-MPs could treat liver fibrosis without pneumotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=85035024564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035024564&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2017.11.031

DO - 10.1016/j.biomaterials.2017.11.031

M3 - Article

C2 - 29190497

AN - SCOPUS:85035024564

VL - 156

SP - 45

EP - 55

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -